This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.
new dosing option in locally advanced, unresectable non-small cell lung cancer (NSCLC). ... The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC).
The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... The TIGIT-targeting treatment is being investigated in a number of
metastatic non-small cell lung cancer (NSCLC), who have received at least one prior systemic therapy. ... Amgen is due to submit the detailed results from the phase 2 study to the International Association for the Study of Lung Cancer World Conference on
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in
Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small
In the third quarter, sales of Keytruda grew by 24% to $2.2bn reflecting growing momentum in a number of non-small cell lung cancer indications, as well as uptake in ... other areas including adjuvant melanoma and bladder cancer.
More from news
Approximately 9 fully matching, plus 649 partially matching documents found.
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical ... For novel therapies (including medicines aimed at rare
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
Amgen brought the first approved BiTE molecule targeting CD19 to patients and we continue to pioneer the bispecific space by exploring this technology across solid tumors, such as small-cell lung ... the other is designed to engage with any
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute. ... The NF1 gene provides instructions to make neurofibromin which acts as a tumour suppressant but if it mutates, tumour cell growth
For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy ... The challenges around precision medicine are illustrated perfectly
More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech. ... Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung
Takes control as company prepares to take novel cancer drug to proof-of-concept. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer. ... Non-small cell lung cancer treatments,
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...